ODT News and Press, Odonate Therapeutics Inc. From 08/29/20

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Stocks wrapped up another strong week on a high note, as the Federal Reserve’s new, more tolerant approach to inflation rippled t...

Gainers:  Just Energy Group (NYSE: JE ) +35% . More news on: Just Energy Group Inc., Nutanix, Inc., FTS International, Inc., Stocks on the move, Read more ...

Odonate Therapeutics (NASDAQ: ODT ) has priced its public offering of 5,614,036 common shares at a price of $14.25/share, for expected gross proceeds of $80M. More news on: Odonate Therapeutics, Inc., Healthcare stocks news, , Read more ...

Gainers:  Cancer Genetics (NASDAQ: CGIX ) +142% . More news on: Cancer Genetics, Inc., iBio, Inc., Sonnet BioTherapeutics Holdings, Inc., Stocks on the move, , Read more ...

Odonate Therapeutics (NASDAQ: ODT ) says that the CONTESSA (Phase 3) trial evaluating lead candidate tesetaxel in metastatic breast cancer (MBC) patients  met the primary endpoint of improved Progression-free Survival (PFS), with median PFS of 9.8 months for tesetaxe...

Onconova Therapeutics (NASDAQ: ONTX )   -71%  after announcing topline results from Phase 3 INSPIRE trial. More news on: Onconova Therapeutics, Inc., Northern Dynasty Minerals Ltd., Odonate Therapeutics, Inc., Stocks on the move, , Read more ...

CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Median PFS Was 9.8 Months for Tesetaxel Plus a Reduced Dose of C...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will hold a conference call on Monday, August 24, 2020 at 8:30 a.m. ET. To partici...

Odonate Therapeutics (NASDAQ: ODT ) : Q2 GAAP EPS of -$1.09 misses by $0.08 . More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

  Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020. As of ...